- Poster presentation
- Open Access
Results of a tissue engineered pulmonary valve in humans assessed with CMR
© Rickers et al; licensee BioMed Central Ltd. 2010
- Published: 21 January 2010
- Pulmonary Valve
- Pulmonary Valve Replacement
- Inversion Recovery Sequence
- Pulmonary Valve Stenosis
- Valve Conduit
Tissue-engineered (TEng) valves have recently been developed as an alternative to pulmonary valve replacement with homograft conduits to improve device life-time and function.
To evaluate with advanced CMR techniques the morphological and functional properties of a decellularized porcine xenograft valve conduit (Matrix-P™) and its successor product with additional equine pericardium sheathing (Matrix-P-Plus™; AutoTissue, Germany).
TEng valves had been implanted into the right ventricular outflow tract of 12 pts (age: 15 ± 8,5 yrs; Matrix-P™ n = 7; Matrix-P-Plus™ n = 5) due to pulmonary stenosis or insufficiency within a median 5 months range (2-7 months) before a comprehensive follow-up by CMR. Echocardiography was suspicious of accelerated blood flow in the main pulmonary artery in 10 of those. The severity of the pulmonary valve stenosis was assessed by gradient echo cine MRI (FOV 270 × 270 mm, voxel size 1.88 × 1.94 × 5 mm, TR/TE/α = 4.4 ms/2.7 ms/15°) and phase-contrast velocity mapping (FOV 270 × 270 mm, voxel size 1.64 × 1.4 × 7 mm, TR/TE/α = 15 ms/2.5 ms/30°, velocity encoding (VENC) = 400 cm/s) were applied. For tissue characterisation late enhancement imaging (Gd 0.1 mmol/kg) using an ECG triggered 3D inversion recovery sequence (TR/TE/α= 3.7 ms/1.8 ms/15°; voxel size 1.17 × 1.27 × 10 mm) and T1 and T2 weighted turbo spin echo sequences were utilized.
In 9 pts (33%) CMR detected a significant conduit stenosis (Vmax 3.7 ± 1,3 m/s) with mild or moderate insufficiency (RGF 21.3 ± 5.9%) post-surgery. In 3 pts the conduit was considered to be normal. In all pts with a stenosis, T1-weighted images showed significant paravalvular Gadolinium enhancement and wall thickening of the conduit. In 7 pts the "Matrix" valve conduit was replaced by a homograft. Explants were evaluated through histological analysis that showed granulomatous inflammation and increased fibrous tissue content correlating with CMR findings.
Conduit malfunction and paravalvular inflammation was successfully detected with CMR in pts post implantation of a decellularized pulmonary xenograft. As a consequence of the devastating short term results, use of these grafts was terminated at our center after initial use in 27 patients.
This article is published under license to BioMed Central Ltd.